The overall goal of our research is to understand whether and how the interaction between genetic risk, age related metabolic decline and immune dysfunction contribute to the development and…
As mutations within the protein kinase LRRK2 (Leucine-rich repeat kinase 2) are involved in the pathophysiology of familial, as well as sporadic, PD and lead to increased kinase activity, it is…
Although symptomatic treatment has been successful for PD, no therapy exists that halts or slows down the neurodegenerative process. We hypothesise that clinical trials have consistently failed for…
Whole exome and whole genome sequencing (WES and WGS) on large cohorts of patients have found large numbers of potentially pathogenic genomic variants in patients but it is difficult to convincingly…
Neurodegenerative diseases such as PD are characterized by numerous alterations in protein composition of the brain. However, the relevant brain cells are for obvious reasons practically …
The Defeat Parkinson’s Platform is supported by institutional funds from the Charitable Hertie Foundation, the University of Tübingen, the German Center for Neurodegenerative Diseases (DZNE) and by…
Researchers and physicians of the Defeat Parkinson's Platform are active and often leading members of many international research networks:
the International Parkinson's Disease Genomics…
The DZNE Tübingen, the HIH and the clinical neurology department have created a state of the art platform for genomic research, using transcriptomics, epigenetics, proteomics and high-throughput…
